Asacol foam (mesalazine rectal foam) / Nogra Pharma - LARVOL DELTA

Antioxidant and anti-inflammatory effects of Equisetum arvense L. on acid-induced ulcerative colitis in rats. (PubMed, Sci Rep) - "Eighty-one male Sprague Dawley rats were acquired and randomly allocated into nine equal groups: healthy control group, negative control groups (receiving normal saline and carboxymethyl cellulose gel base), positive control groups (receiving asacol rectally and mesalazine orally), and test groups treated with different amounts of HAEA...This study showed promising therapeutic effects in all HAEA-treated groups, particularly HAEA gel 10% rectal enema in the induced UC rat model compared to conventional treatments. Both in vivo and in vitro findings indicate that EAL has the potential to be used as an additive therapeutic strategy in UC patients."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL1B • MPO

SIMILAR EFFICACY OF MESALAZINE (ASACOL) AND OZANIMOD (ZEPOSIA) FOLLOWING INDUCTION TREATMENT IN 5-ASA-EXPOSED ADVANCED THERAPY-NAÏVE ULCERATIVE COLITIS PATIENTS (UEGW 2024) - "Similar efficacy was observed between Mesalazine and Ozanimod in moderate to severe UC, most likely due to impact of these drugs on reducing local inflammation. This highlights the importance of considering dose optimisation of mesalazine before escalating to other agents."

Clinical • Metastases • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

ASACOL 1,600mg, One Tablet Once Daily to Maintain Remission (IMKASID 2024) - "Starting with the development of infliximab in the late 1990s, various biologics have been developed and used, and it is no e xaggeration to say that we are now living in the biologics era, and the current treatment of ulcerative colitis is dominated by various biologics...Several techniques have been developed for effective drug transport, the first being sulfasalazine, which is a sulfapyridine conjugated to 5 -ASA with an azo bond...Recently, ASACOL® 1600 mg with the OPTICORE® delivery system is widely used, which combines pH -dependent release with bacterial -sensitive polymer release in contact with bacterial enzymes in the colon, allowing patients to take once daily. The OPTICORE® system helps patients achieve high therapeutic efficacy while improving patient convenience."

Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome. (PubMed, J Control Release) - "Further, both 5-ASA and sulfasalazine significantly reduced the growth of the faecal microbiota sourced from six healthy humans. The findings support that the approach selected for colonic drug delivery could significantly influence the effectiveness of UC treatment, and highlight that drugs licensed for UC may differentially impact the growth and functioning of the colonic microbiota."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Expanded table: Some drugs for inflammatory bowel disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Drugs for inflammatory bowel disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Table: safety of drugs for IBD in pregnancy. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis (clinicaltrials.gov) - P=N/A | N=177 | Completed | Sponsor: Chinese University of Hong Kong | Unknown status ➔ Completed

Trial completion • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

CB-01-35: A RIFAMYCIN IN SITU GEL ENEMA THAT DEMONSTRATES SUPERIOR EFFICACY COMPARED TO MESALAMINE AND DEXAMETHASONE IN A RAT OXAZOLONE MODEL OF ULCERATIVE COLITIS (DDW 2023) - "Given that Rifaximin, an ansamycin class antibiotic, has demonstrated efficacy in some UC patients, we sought to evaluate Rifamycin SV (rifamycin) as a potential therapeutic...The clinical parameters such as body weight changes, macroscopic damage score and mucosal damage area score were compared to mesalamine enema (Asacol® foam, commercially available in Europe), intraperitoneal dexamethasone and rifamycin gel placebo (vehicle)...We propose that the CB-01-35 rifamycin in situ gel enema formulation provides a longer duration of exposure of this dual-acting antibiotic / anti-inflammatory drug at the site of the damaged intestinal mucosa. As such, this provides a dual pharmacological activity leading to superior efficacy, relative to Asacol foam or dexamethasone, in this UC animal model."

Preclinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immune Modulation • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CXCL8 • CYP3A4 • NF-κβ

Design, Development, and Optimisation of Smart Linker Chemistry for Targeted Colonic Delivery-In Vitro Evaluation. (PubMed, Pharmaceutics) - "For both prodrugs, the extent of release was comparable to that of the commercial product Asacol. This study provides initial proof of concept regarding the use of a cyclisation-activated prodrug for colon delivery and suggests that release characteristics still vary on a case-by-case basis."

Journal • Preclinical • Gastrointestinal Disorder

Development of bicarbonate buffer flow-through cell dissolution test and its application in prediction of in vivo performance of colon targeting tablets. (PubMed, Eur J Pharm Sci) - "Mesalazine colon targeting tablets of a generic development product (test formulation, TF; Mesalazine 400 mg tablet) and the original product (reference formulation, RF; Asacol® 400 mg tablet) were used as model formulations...In conclusion, the bicarbonate FTC method was constructed for the first time in this study. This method is simple and practically useful for predicting in vivo performance of colon targeting tablets during drug development."

Journal • Preclinical

"Allergic to Sulfa meds., Dx w/ moderate U.C. mid-1990s. Had to take Prednisone & Asacol for year +. Neck herniated discs 9/97, Lumbar 1 1998, PsA & Uterine Vasculitis Dx '99 & 2000. #OneBigItis😎" (@lylldy)

Vasculitis

Implementation and Evaluation of Two Nudges in a Hospital's Electronic Prescribing System to Optimise Cost-Effective Prescribing. (PubMed, Healthcare (Basel)) - "The first nudge provided simple cost information (percentage cost-difference between two brands of mesalazine: Asacol and Octasa)...For example, although for legal reasons the cost of medicine cannot be displayed, we were able to present aggregated cost information to the prescribers. Future research could reveal more behavioural factors that facilitate medication optimisation."

HEOR • Journal

"US patients seeing UK Humira cost = Asacol cost https://t.co/3BmZqHTH5f" (@ibddoctor)

Clinical

Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis (clinicaltrials.gov) - P4 | N=149 | Completed | Sponsor: Sheba Medical Center | Recruiting ➔ Completed

Trial completion • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Clinical translation of advanced colonic drug delivery technologies. (PubMed, Adv Drug Deliv Rev) - "Harnessing these advanced technologies offers new possibilities for drug delivery via the colon, including the delivery of biopharmaceuticals, vaccines, nutrients, and microbiome therapeutics for treatment of both local and systemic diseases. This review details the latest advances in colonic drug delivery with an emphasis on emerging therapeutic opportunities and clinical technology translation."

Clinical • Journal • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Ozanimod (Zeposia) for ulcerative colitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Efficacy and safety of mesalazine, rifaximin, alone or as extemporary combination, in the treatment of symptomatic uncomplicated diverticular disease of colon Appropriatezza d¿uso di Mesalazina e/o di Rifaximina nel trattamento della malattia diverticolare sintomatica non complicata del colon (clinicaltrialsregister.eu) - P4; N=820; Ongoing; Sponsor: DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II

Clinical • New P4 trial • Gastroenterology • Gastrointestinal Disorder • CRP

"i am taking predisone now as asacol and oentasa did not control///and i take ocycodne for daily chronic pain" (@MrNice33102958)

Pain

Medicinal products with controlled drug release for local therapy of inflammatory bowel diseases from perspective of pharmaceutical technology. (PubMed, Ceska Slov Farm) - "Specifically, it focuses on pharmaceutical drugs containing 5-aminosalicylic acid (Asacol®, Pentasa®, Salofalk®) and budesonide (Budenofalk®, Cortiment®, Entocort®). As a part of this paper, basic recommendations and practical information that can be used in clinical practice are also given."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

The Therapeutic Effect of Shark Liver Oil in a Rat Model of Acetic Acid-Induced Ulcerative Colitis. (PubMed, Evid Based Complement Alternat Med) - "Eighty induced UC rats were randomly divided into ten equal groups and received the following treatments for seven days: 1 ml of normal saline rectally, 1 ml of gel base (carboxymethyl cellulose) rectally, 10 mg/kg of Asacol rectally, 10 mg/kg of mesalazine orally, 5% gel form of SLO rectally, 10% gel form of SLO rectally, 200 mg of SLO orally, and 400 mg of SLO orally. There were no significant changes detected in the mean rank among different groups. Our data indicate that SLO supplementation could improve the amelioration of acetic acid-induced UC in rats due to its antioxidant effects."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. (PubMed, Cochrane Database Syst Rev) - "There is high-certainty evidence that 5-ASA is superior to placebo for maintenance therapy in UC. There is high-certainty evidence that 5-ASA is inferior compared to SASP. There is probably little or no difference between 5-ASA and placebo, and 5-ASA and SASP in commonly reported AEs such as flatulence, abdominal pain, nausea, diarrhea, headache, and dyspepsia. Oral 5-ASA administered once daily has a similar benefit and harm profile as conventional dosing for maintenance of remission in quiescent UC."

Clinical • Journal • Review • Dyspepsia • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pain • Ulcerative Colitis

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. (PubMed, Cochrane Database Syst Rev) - "There is high-certainty evidence that 5-ASA is superior to placebo, and moderate-certainty evidence that 5-ASA is not more effective than SASP. Considering relative costs, a clinical advantage to using oral 5-ASA in place of SASP appears unlikely. High-certainty evidence suggests 5-ASA dosed once daily appears to be as efficacious as conventionally-dosed 5-ASA. There may be little or no difference in efficacy or safety among the various 5-ASA formulations."

Clinical • Journal • Review • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pain • Ulcerative Colitis

"I remember Asacol tablets passing through, seeing them, in tact, in the toliet 🚽 #MondayNightIBD" (@ibd_reporter)

Similar Pharmacokinetics of Three Dosing Regimens Comprising Two Oral Delayed-Release Mesalamine Formulations in Healthy Adult Volunteers: Randomised, Open-Label, Parallel-Group Study. (PubMed, Br J Clin Pharmacol) - P1 | "Plasma and urine pharmacokinetics for Asacol TID, Asacol QD and Lialda QD are similar, suggesting similar daily systemic exposures can be obtained with either TID or QD dosing. NCT00751699."

Clinical • Journal • PK/PD data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis